Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system

Yaneth Osorio, Bruno Travi, Adam R. Renslo, Alex-Giovanny Peniche-Trujillo, Peter Melby

Research output: Chapter in Book/Report/Conference proceedingChapter

44 Citations (Scopus)

Abstract

Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity. Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of <-1.96 (p<0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50% cytotoxicity in the HepG2 cell line to the concentration that caused 50% reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids (10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%). Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.

Original languageEnglish (US)
Title of host publicationPLoS Neglected Tropical Diseases
Volume5
Edition2
DOIs
StatePublished - Feb 2011

Fingerprint

Visceral Leishmaniasis
Leishmania donovani
Parasites
Luciferases
Parasite Load
Small Molecule Libraries
Furans
Phenothiazines
Host-Parasite Interactions
Poisons
Leishmania
Terpenes
Hep G2 Cells
Amphotericin B
Immunosuppressive Agents
Alkaloids
Cricetinae
Pharmaceutical Preparations
Spleen
Cell Line

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system. / Osorio, Yaneth; Travi, Bruno; Renslo, Adam R.; Peniche-Trujillo, Alex-Giovanny; Melby, Peter.

PLoS Neglected Tropical Diseases. Vol. 5 2. ed. 2011. e962.

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{b17363f13a52476a945218a149274d6b,
title = "Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system",
abstract = "Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity. Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0{\%}) with a Z score of <-1.96 (p<0.05). Eighty-four (2.1{\%}) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50{\%} cytotoxicity in the HepG2 cell line to the concentration that caused 50{\%} reduction in the parasite load). Sixty-nine (82{\%}) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14{\%}), alkaloids (10{\%}), aromatics (11{\%}), terpenes (8{\%}), phenothiazines (7{\%}) and furans (5{\%}). Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.",
author = "Yaneth Osorio and Bruno Travi and Renslo, {Adam R.} and Alex-Giovanny Peniche-Trujillo and Peter Melby",
year = "2011",
month = "2",
doi = "10.1371/journal.pntd.0000962",
language = "English (US)",
volume = "5",
booktitle = "PLoS Neglected Tropical Diseases",
edition = "2",

}

TY - CHAP

T1 - Identification of small molecule lead compounds for visceral leishmaniasis using a novel ex vivo splenic explant model system

AU - Osorio, Yaneth

AU - Travi, Bruno

AU - Renslo, Adam R.

AU - Peniche-Trujillo, Alex-Giovanny

AU - Melby, Peter

PY - 2011/2

Y1 - 2011/2

N2 - Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity. Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of <-1.96 (p<0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50% cytotoxicity in the HepG2 cell line to the concentration that caused 50% reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids (10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%). Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.

AB - Background: New drugs are needed to treat visceral leishmaniasis (VL) because the current therapies are toxic, expensive, and parasite resistance may weaken drug efficacy. We established a novel ex vivo splenic explant culture system from hamsters infected with luciferase-transfected Leishmania donovani to screen chemical compounds for anti-leishmanial activity. Methodology/Principal Findings: This model has advantages over in vitro systems in that it: 1) includes the whole cellular population involved in the host-parasite interaction; 2) is initiated at a stage of infection when the immunosuppressive mechanisms that lead to progressive VL are evident; 3) involves the intracellular form of Leishmania; 4) supports parasite replication that can be easily quantified by detection of parasite-expressed luciferase; 5) is adaptable to a high-throughput screening format; and 6) can be used to identify compounds that have both direct and indirect anti-parasitic activity. The assay showed excellent discrimination between positive (amphotericin B) and negative (vehicle) controls with a Z' Factor >0.8. A duplicate screen of 4 chemical libraries containing 4,035 compounds identified 202 hits (5.0%) with a Z score of <-1.96 (p<0.05). Eighty-four (2.1%) of the hits were classified as lead compounds based on the in vitro therapeutic index (ratio of the compound concentration causing 50% cytotoxicity in the HepG2 cell line to the concentration that caused 50% reduction in the parasite load). Sixty-nine (82%) of the lead compounds were previously unknown to have anti-leishmanial activity. The most frequently identified lead compounds were classified as quinoline-containing compounds (14%), alkaloids (10%), aromatics (11%), terpenes (8%), phenothiazines (7%) and furans (5%). Conclusions/Significance: The ex vivo splenic explant model provides a powerful approach to identify new compounds active against L. donovani within the pathophysiologic environment of the infected spleen. Further in vivo evaluation and chemical optimization of these lead compounds may generate new candidates for preclinical studies of treatment for VL.

UR - http://www.scopus.com/inward/record.url?scp=79952474741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952474741&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0000962

DO - 10.1371/journal.pntd.0000962

M3 - Chapter

VL - 5

BT - PLoS Neglected Tropical Diseases

ER -